Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine
- PMID: 18647300
- DOI: 10.1111/j.1464-410X.2008.07845.x
Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine
Abstract
Objectives: To assess the utility of perceived control over ejaculation ('control') in the evaluation of treatment benefit in men with premature ejaculation (PE), and to compare effects associated with a two-category or greater increase in this variable between men receiving dapoxetine and placebo.
Patients and methods: This subanalysis used combined data from all treatment groups in an integrated analysis of two identically designed, 12-week, double-blind, randomized, placebo-controlled trials of dapoxetine. Men (2614) met the Diagnostic and Statistical Manual of Mental Disorders (fourth edition, text revision) criteria for PE, had a stopwatch-measured intravaginal ejaculatory latency time (IELT) of < or =2 min in > or =75% of events in a 2-week baseline period, and self-reported moderate or severe PE. Men received placebo or dapoxetine 30 or 60 mg, 1-3 h before intercourse. The stopwatch-measured IELT was recorded for each episode; the patient-reported global impression of change (PGI; 7-point scale, 'much worse' to 'much better'), control and satisfaction with sexual intercourse (5-point scales, 'very poor' to 'very good') were assessed monthly. The utility of a two-category or greater increase in control was evaluated by examining the relationship of this variable with IELT and satisfaction with sexual intercourse.
Results: Of 2341 men with baseline and endpoint assessments, 96.8% reported 'very poor' or 'poor' control at baseline, and 748 (32%) reported a two-category or greater increase in control after treatment. More than 95% of those men rated their PE as 'slightly better', 'better', or 'much better' on the PGI; 67.1% gave ratings of 'better' or 'much better.' They also had greater improvements in IELT than men with less than a two-category increase in control, with a mean (sd) change from baseline of 3.7 (4.3) vs 0.77 (1.8) min, respectively, and a greater percentage reported good or very good satisfaction with sexual intercourse than men with less than a two-category increase in control (74% vs 19%, respectively). Nausea, headache and upper respiratory tract infection were the most common adverse events reported by men with a two-category or greater increase in control (15.8%, 7.4% and 6.6%, respectively) and those without (8.5%, 5.5% and 6.5%, respectively). The proportions of men with a two-category or greater increase in control with dapoxetine 30 and 60 mg were 36.3% and 44.5%, respectively (vs 15% with placebo).
Conclusions: A two-category or greater increase in control (5-point scale) is useful for assessing the treatment benefit in men with PE; it corresponds with improvements in the man's perception of his condition, substantially greater prolongation of IELT, and higher levels of satisfaction with sexual intercourse.
Similar articles
-
Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial.BJU Int. 2009 Mar;103(5):651-8. doi: 10.1111/j.1464-410X.2008.08165.x. Epub 2008 Nov 18. BJU Int. 2009. PMID: 19021601 Clinical Trial.
-
Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation.J Sex Med. 2010 Jun;7(6):2243-2252. doi: 10.1111/j.1743-6109.2010.01793.x. Epub 2010 Mar 30. J Sex Med. 2010. PMID: 20367770 Clinical Trial.
-
Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine.J Sex Med. 2010 Jan;7(1 Pt 1):256-68. doi: 10.1111/j.1743-6109.2009.01560.x. Epub 2009 Oct 29. J Sex Med. 2010. PMID: 19878447 Clinical Trial.
-
Dapoxetine: in premature ejaculation.Drugs. 2010 Jul 30;70(11):1433-43. doi: 10.2165/11204750-000000000-00000. Drugs. 2010. PMID: 20614950 Review.
-
A benefit-risk assessment of dapoxetine in the treatment of premature ejaculation.Drug Saf. 2012 May 1;35(5):359-72. doi: 10.2165/11598150-000000000-00000. Drug Saf. 2012. PMID: 22452563 Review.
Cited by
-
Progressive arousal: a new concept and definition for premature ejaculation.Sex Med. 2023 Apr 27;11(2):qfad014. doi: 10.1093/sexmed/qfad014. eCollection 2023 Apr. Sex Med. 2023. PMID: 37124144 Free PMC article.
-
Does Bother/Distress Contribute to the Diagnosis of Premature Ejaculation?Sex Med. 2022 Oct;10(5):100548. doi: 10.1016/j.esxm.2022.100548. Epub 2022 Aug 8. Sex Med. 2022. PMID: 35952615 Free PMC article.
-
The Tenuous Role of Distress in the Diagnosis of Premature Ejaculation: A Narrative Review.Sex Med. 2022 Oct;10(5):100546. doi: 10.1016/j.esxm.2022.100546. Epub 2022 Jul 26. Sex Med. 2022. PMID: 35905650 Free PMC article. Review.
-
Are the Criteria for the Diagnosis of Premature Ejaculation Applicable to Gay Men or Sexual Activities Other than Penile-Vaginal Intercourse?Sex Med. 2022 Jun;10(3):100516. doi: 10.1016/j.esxm.2022.100516. Epub 2022 Apr 25. Sex Med. 2022. PMID: 35477122 Free PMC article.
-
Perceptions, Expectations, Preferences, and Attitudes Toward Premature Ejaculation, Its Diagnosis and Topical Treatment with Fortacin™ Spray: Results from an Expert Panel Discussion.Res Rep Urol. 2020 Jul 2;12:211-216. doi: 10.2147/RRU.S250301. eCollection 2020. Res Rep Urol. 2020. PMID: 32670915 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous